C
Casma Therapeutics
Harnessing the natural cellular process of autophagy to design powerful new medicines for a broad range of diseases
About Casma Therapeutics
Casma Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically in the field of disease treatment. The company's primary focus is on reprogramming autophagy, a natural process in the body that removes damaged components within cells to maintain and improve health. Casma's innovative approach involves enhancing this process to treat diseases that current drugs have been unable to effectively target.
The company's business model revolves around its proprietary PHLYT™ (Phagosome-Lysosome Targeting) platform. This platform initiates target-specific autophagic degradation of new disease targets, regardless of their size or complexity. In simpler terms, it enhances the body's natural process of removing damaged components in cells to treat diseases.
Casma Therapeutics serves a broad range of clients, including patients suffering from diseases that are currently difficult to treat with existing drugs. The company generates revenue through the development and commercialization of its PHLYT™ platform and related treatments.
Recently, the company has made significant strides in its operations, raising $46.0 million in Series C funding and presenting at the Stifel 2022 Healthcare Conference. These developments indicate a positive trajectory for the company's growth and its potential to make a significant impact in the healthcare sector.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 40.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Mar 2026 | $7.6M | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
| SERIES COther financing | Nov 2022 | $46M | $293M | Third Rock Ventures · The Column Group · Astellas Venture · Ono Venture Investment | ↗ |
Growth signals
Latest recorded traffic for Casma Therapeutics is 2K monthly website visits, down 9.1% over the last three months. Casma Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Michael J. Fox Foundation for Parkinson's Research
Series A4 investors entered at this stage
Third Rock Ventures
The Column Group
Schroder Adveq
Eventide Asset Management
Series B and later7 investors entered at this stage
Astellas Venture
Ono Venture Investment
Mirae Asset Venture Investment
Eisai
Amgen Ventures- ECEuclidean Capital
Schroders Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Casma Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Casma Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.